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Introduction
Rheumatoid arthritis (RA) is a multifactorial, chronic 
inﬂ ammatory and immune-mediated syndrome that 
causes joint damage, but can in selected patients present 
with diﬀ erent tissue and organ involvement [1]. Following 
the 2010 American College of Rheumatology/European 
League Against Rheumatism RA classiﬁ cation criteria, an 
overall score ≥6/10 is needed for classiﬁ cation of a patient 
as having RA [2]. However, these criteria should only be 
used if a clinical case of RA is likely; namely the patient 
should have at least one joint with a deﬁ nite clinical 
synovitis, not explained by another disease.
Th e sensitivity of these criteria was recently measured 
to be higher than its precursor of 1987 while having a 
lower speciﬁ city [3]. Notably, in RA chronic synovial 
tissue inﬂ ammation and hyperplasia drive articular 
des truc tion and bone erosion, leading to functional 
decline and disability [4].
Biological disease-modifying antirheumatic drugs 
(DMARDs) target particular soluble extracellular 
mediators (that is, cytokines) or cell surface molecules 
(that is, CD20 or CD86) with high speciﬁ city [5]. Con-
versely, conventional synthetic DMARDs usually act 
within cells, but nonetheless may also have speciﬁ c 
targets such as that designed to target Janus kinases and 
constituting the ﬁ rst targeted synthetic DMARD, named 
tsDMARD, following a proposed new nomenclature [6].
On the other hand, glucocorticoids (GCs), used for 
decades in the treatment of RA, are eﬀ ective in relieving 
signs and symptoms of the disease and also interfere with 
radiographic progression, either as monotherapy or in 
combination with synthetic DMARDs [7]. An inadequate 
secretion of GCs from the adrenal gland, in relation to 
stress and inﬂ am mation, seems to play an important role 
in the patho genesis and disease progression of RA. [7] As 
a matter of fact, in the most recent European League 
Against Rheumatism (EULAR) recommendations for the 
management of RA, low-dose GCs have been conﬁ rmed 
as at least part of the initial treatment strategy (in 
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combination with one or more conventional synthetic 
DMARDs) for at least 6 months [8].
Understanding the anti-infl ammatory actions of 
glucocorticoids
Despite being among the most eﬀ ective anti-inﬂ am ma-
tory treatments for chronic inﬂ ammatory diseases, the 
mechanisms by which GCs eﬀ ect repression of inﬂ am-
matory gene expression remain only incompletely under-
stood. Direct interaction of the GC receptor (nuclear 
receptor subfamily 3, group C, member 1 (NR3C1)) with 
inﬂ ammatory transcription factors to repress transcrip-
tional activity – that is, transrepression – represents one 
mechanism of action. However, transcriptional activa-
tion – or transactivation – by the GC receptor (NR3C1) 
also represents an important mechanism of GC action. 
In addition, GCs rapidly and profoundly increase 
expression of multiple genes, many with properties 
consistent with the repression of inﬂ ammatory gene 
expression [9]. On the other hand, RNA-binding proteins 
and microRNA play an important role in the 
pathophysiology of chronic inﬂ ammation, and seem to 
have promising value as mechanisms conveying the anti-
inﬂ ammatory eﬀ ect of exogenous GCs [10].
In general, GCs provide inhibition of any inﬂ ammatory 
process that seems to be dose dependent, and both a 
long-term genomic and a short-term nongenomic eﬀ ect 
are recognized [11]. Of course, the known side eﬀ ects of 
GCs are strongly dose dependent: the longer the therapy 
or the higher the dose, the more relevant the GC side 
eﬀ ects appear [12]. Th e nomenclature for diﬀ erent GC 
dosages is reported in Figure 1.
Genomic action of glucorticoids
As mentioned, and regarding the genomic action, GCs 
provide most of their eﬀ ects using the cytosolic gluco-
corticoid receptor (cGR)  – being part of a multiprotein 
receptor complex also consisting of heat shock proteins 
and several kinases [13,14].
Since GCs are lipophilic, they are able to pass through 
the plasma membrane and interact with their distinct 
receptor within the cells. Of note, the 17-hydroxy, 
21-carbon steroid conﬁ guration of GCs is the reason for 
their lipophilicity and the successive receptor binding, 
and is applicable to both prednisone and prednisolone 
and other GCs [15].
Following the GC binding to the cGR, the receptor-
associated proteins dissociate and the complex of GC/
cGR translocates into the nucleus, binding as a homo-
dimer to speciﬁ c DNA binding sites, so-called GC 
response elements [13]. Th is genomic action, termed 
transactivation, leads to the synthesis of anti-inﬂ am-
matory proteins (such as, for example, annexin (lipo-
cortin) 1, IκB, interleukin (IL)-10) as well as regulatory 
proteins, involved also in metabolism and various GC 
side eﬀ ects. On the other hand, GC/cGR monomers are 
able to negatively interfere with transcription factors 
(genomic action termed transrepression) such as nuclear 
factor-κB, activator protein-1 and nuclear factor for 
activated T cells, as a consequence reducing the expres-
sion of proinﬂ ammatory proteins such as IL-1, IL-6 or 
tumor necrosis factor (TNF) alpha [16,17]. Interestingly, 
by decreasing TNFα synthesis, GCs probably lead to 
reduction of inﬂ ammatory osteoporosis and joint 
erosions since TNF physiologically induces the produc-
tion of receptor activator of nuclear factor-κB ligand that 
appears to be involved in generation of joint erosions by 
activating osteoclasts [18].
In conclusion, transrepression and transactivation 
seem to provide the genomic anti-inﬂ ammatory actions 
exerted especially by low-dose prednisone [19]. A low-
dose, modiﬁ ed-release formulation of prednisone, ad-
minis tered in the evening, has been developed to counter 
the circadian rise in proinﬂ ammatory cytokine levels that 
contributes to disease activity and seems to not interfere 
with the hypothalamic–pituitary–adrenal (HPA) function 
[20,21]. Modiﬁ ed-release prednisone might therefore 
repre sent the way to further optimize the DMARD 
activity exerted by low-dose GCs in RA [22].
Nongenomic action of glucocorticoids
Th e administration of prednisone, especially at high 
dosages, induces a rapid clinical improvement that is 
sometimes too fast to be explained by genomically 
mediated action, and the presence of nongenomic action 
is emphasized by the fact that the cGRs are completely 
occupied when administering 100 to 200  mg/day pred-
nisone [23,24] (Figure 1).
Th e proposed nongenomic action for mechanisms that 
are not cGR-mediated includes their speciﬁ c interaction 
with the cGR  – resulting, for example, in nongenomic 
inhibition of arachidonic acid release  – and physio-
chemical interactions with cellular membranes, resulting 
in nongenomic compromising of ion cycling across the 
membranes and cell energy supply, and consequently 
immune/inﬂ ammatory cell function [16,25]. Generally, 
the rapid nongenomic GC eﬀ ects that appear quickly, 
from several seconds to minutes, seem to be obtained by 
three diﬀ erent mecha nisms: physicochemical 
interactions with components of the cellular membranes 
(nonspeciﬁ c nongenomic eﬀ ects); membrane-bound GC 
receptor-mediated non genomic eﬀ ects; and cGR-
mediated nongenomic eﬀ ects [11,26]. Th e extraordinary 
wide range of GC actions can be explained by GC 
receptor presence in three cell com part ments: nucleus, 
cytoplasm, and plasma membrane (Figure 2).
Whereas the optimization of the genomic action (by 
low-dose administration) is achieved via GC nighttime 
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availability (modiﬁ ed-release prednisone release around 
3:00  a.m.), by respecting the circadian rhythm of both 
endogenous GC synthesis and night activation of the 
immune/inﬂ ammatory reaction, on the other hand the 
nongenomic action (high doses) should be obtainable at 
almost any time of the day when fast eﬀ ects are required 
[27-30].
From the early steps to the more recent evidence 
for the use of low-dose glucocorticoids in RA
Th e introduction of GCs for treatment of RA in 1948 and 
the dramatic clinical responses in a report published in 
1949 originated the attribution of the Nobel Prize in 
Physiology and Medicine to Hench, Kendall and 
Reichstein. Interestingly, the Mayo Clinic group that 
discovered GCs recommended as early as 1955 that doses 
equivalent to 5 to 10 mg/day prednisone should be used 
in treatment of RA [31]. However, a dose of 20  mg/day 
prednisolone was used in clinical trials in 1960 (after GCs 
were available for treatment) to compare with aspirin, 
and while DMARD properties were well documented in 
RA patients, the conventional wisdom at that time was 
that low doses were not disease modifying (that is, did 
not decrease joint damage as assessed radiographically) 
[32,33].
Th erefore, by the late 1950s, oral GCs were considered 
appropriate in RA only for severe, potentially life-
threatening situations or as short-term bridging therapy 
while awaiting results of what was regarded as remission-
inducing DMARD therapy [34]. However, the ﬁ rst 
clinical trial involving low-dose GCs was reported in the 
early 1960s, and compared the evening dose versus the 
morning dose [34]. Th e authors stated that their clinical 
practice of treating all patients with 7.5  mg/day or less 
was based on ‘observations made in the course of study-
ing the phenomenon of morning stiﬀ ness’ [35,36].
In addition to the clinical eﬃ  cacy of the low dose, the 
authors observed that overall 50% of RA patients 
preferred the evening dose and concluded that low-dose 
GC therapy (5  mg prednisolone) at night was more 
eﬃ  cacious than the morning dose for management of 
most RA patients.
No clinical trials involving low-dose prednisone were 
performed until 19  years later when a well-performed, 
double-blind study was published in the early 1980s [37]. 
Th is study was very important since prednisone (5  mg/
day) was taken every morning and added to other drugs 
in 18 RA patients. Sixteen RA patients were given a 
placebo in this double-blind study. After 24  weeks, all 
patients were treated with placebo. Slight functional 
improvement was noted in the prednisone group during 
the 24-week period, but deterioration after switching to 
placebo was sustained for at least 8 weeks. Interestingly, 
progression of hand erosions occurred in one pred-
nisone-treated patient and in four controls. Th e authors 
concluded that low doses of prednisone may be useful as 
bridge therapy between nonsteroidal anti-inﬂ ammatory 
therapy and use of DMARDs.
Figure 1. Relationship between diff erent glucocorticoid doses 
(prednisone equivalent milligrams), intensity of the therapeutic 
eff ect (arbitrary units), and genomic/nongenomic mechanism 
of action. Low-dose therapy, <7.5 mg/day; medium-dose therapy, 
7.5 up to 30 mg/day; high-dose therapy, 30 up to 100 mg/day; very 
high-dose therapy, >100 mg/day; pulse therapy, >250 mg/day for 
a few days [12]. *When administering 100 to 200 mg prednisone 
per day, all cytosolic glucocorticoid (GC) receptors are occupied 
(nongenomic action) [23].
Figure 2. Representation of major physicochemical 
glucocorticoid interactions with components of the cellular 
membrane. Membrane glucocorticoid receptor (mGR)-mediated 
nongenomic eff ects together with cytosolic glucocorticoid receptor 
(cGR)-mediated genomic eff ects on nuclear glucocorticoid response 
elements (GRE) (including inhibition of the nuclear factor-κB complex 
(NF-κB)) and resultant protein synthesis that can cause increased 
expression of regulatory – including anti-infl ammatory – proteins 
(transactivation) or decreased production of proinfl ammatory 
proteins (transrepression) [16]. GC, glucocorticoid; GR, glucocorticoid 
receptor.
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Today there is clear evidence that GC therapy, 
especially long-term, low-dose treatment, slows down 
radiographic progression by at least 50% when given to 
patients with early RA, thus satisfying the conventional 
deﬁ nition of a DMARD [38]. In addition, long-term 
follow-up data suggest that treatment strategies which 
include GC therapy may favorably alter the disease 
course even after discontinuation of the GCs. Some 
recent studies such as the Better Anti-rheumatic 
Farmaco therapy (BARFOT) study, the Utrecht study, the 
Behandel Strategieen (BeSt) study and the oldest 
Combination Th erapy with RA (COBRA) study have now 
reported follow-up for more than 2 years [39-48]. More 
recently, inclusion of low-dose prednisone in a 
methotrexate-based treatment strategy for tight control 
in early RA improved patient outcomes [49].
In conclusion, is now possible to state there is clear 
evidence that low-dose, long-term GC therapy slows 
radiographic progression by at least 50% in treated early 
RA patients and therefore GCs exert disease-modifying 
eﬀ ects [50-52].
The supplementary therapeutic DMARD role of 
low-dose glucocorticoids
Stressful/inﬂ ammatory conditions activate the immune 
system and subsequently the HPA axis through the 
central and peripheral production of cytokines such as 
IL-6 and TNFα [53]. A relative adrenal hypofunction, as 
evidenced by inappropriately normal/low serum cortisol 
levels and reduced sulfated dehydroepiandrosterone 
sulphate serum levels, seems to play an important role in 
the pathogenesis of autoimmune/inﬂ ammatory diseases 
such as RA as well as polymyalgia rheumatica [54,55]. On 
the other hand, chronic inﬂ ammation represents a 
stimulus for the activation of the stress response system 
(in particular, adrenal gland) and, over the long term, a 
subclinical hypofunction of the adrenal glands.
Th e regular observation of reduced cortisol and adrenal 
androgen secretion during testing in RA patients not 
treated with GCs should therefore clearly be regarded as 
relative adrenal insuﬃ  ciency in the setting of a sustained 
inﬂ ammatory process, as shown by high IL-6 levels [56]. 
Th e circadian changes in the metabolism or nocturnal 
secretion of endogenous GCs (reduction) observed in RA 
patients are responsible, in part, for the time-dependent 
changes that are observed in the inﬂ ammatory response 
and related early morning clinical symptoms of the 
disease [57].
Melatonin, another circadian nocturnal hormone that 
is the secretory product of the pineal gland, has been 
implicated in the time-dependent RA inﬂ ammatory 
reaction with eﬀ ects that are opposite to those of GC. As 
a consequence, altered functioning of the HPA axis (early 
morning reduced cortisol production) and of the pineal 
gland (night increased melatonin production) found in 
RA patients seems to be important in the appearance and 
perpetuation of the clinical circadian symptoms of the 
disease [57].
Consistently, human proinﬂ ammatory cytokine pro-
duc tion (for example, TNFα, IL-6, IL-1) exhibits a diurnal 
rhythmicity with peak levels during the night and early 
morning, at a time when plasma cortisol is lowest and 
melatonin levels are highest [58]. In addition, the HPA 
axis with the major hormone cortisol and the sympathetic 
nervous system with epinephrine/nor epinephrine induce 
a shift from energy storage to energy utilization by 
inducing gluconeogenesis, glycogenolysis, and lipolysis 
[59]. Since both systems are activated during an acute 
inﬂ ammatory process, they serve the body by provision 
of energy-rich substrates [60].
Th e clinical and biochemical improvement observed 
after GC therapy in patients with RA and polymyalgia 
rheumatica might thus be attributed to a direct 
dampening of proinﬂ ammatory factors as well as to the 
restoration of the steroid milieu, a sort of GC replacement 
therapy [61].
Conclusions
Although the Mayo Clinic group that discovered GCs 
already recommended in 1955 that doses equivalent to 5 
to 10 mg/day prednisone should be used in treatment of 
RA, much higher dosages have been employed for 
decades, until a recent reevaluation of low doses. GCs 
(low dose) during long-term treatment of RA provide 
most of their eﬀ ects through a genomic action using the 
cGR and then interacting with the target genes that can 
result in increased expression of regulatory  – including 
anti-inﬂ ammatory  – proteins (transactivation) or 
decreased production of proinﬂ ammatory proteins 
(trans repression). An inadequate secretion of GCs from 
the adrenal gland, in relation to chronic inﬂ ammation, 
seems to play an important role in the pathogenesis and 
disease progression of RA. Long-term follow-up data 
now suggest that, especially in early RA patients, 
treatment strategies that include low-dose GC therapy 
(replacement therapy) – better if respecting the circadian 
endogenous production rhythm – may favorably alter the 
disease course, contributing to the DMARD action, and 
this eﬀ ect persists even after their discontinuation 
[62,63].
Key messages
• Th e management of RA is primarily based on the use 
of DMARDs, mainly consisting of synthetic chemical 
compounds (synthetic DMARDs) and biological 
agents (biological DMARDs).
• An inadequate secretion of GCs from the adrenal 
gland, in relation to chronic inﬂ ammation, seems to 
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play an important role in the pathogenesis and disease 
progression of RA [7].
• GC therapy, especially long-term, low-dose treatment 
(replacement therapy), slows down radiographic 
progression by at least 50% when given to patients with 
early RA, hence satisfying the conventional deﬁ nition 
of a DMARD.
• GCs low-dose and long-term provide most of their 
eﬀ ects through a genomic action using the cGR and 
then interacting with the target genes that can result in 
increased expression of regulatory  – including anti-
inﬂ ammatory – proteins (trans activation) or decreased 
production of pro inﬂ ammatory proteins (trans repression).
• Several long-term follow-up studies suggest that RA 
treatment strategies which include GC therapy may 
favorably alter the disease course even after their 
discontinuation.
• A low-dose, modiﬁ ed-release formulation of predni-
sone, administered in the evening, has been developed 
to counteract the circadian rise in proinﬂ ammatory 
cytokine levels that contributes to disease activity and 
might represent the way to further optimize the 
DMARD activity exerted by GCs in RA.
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